dimethyl sulfoxide has been researched along with Hematologic Malignancies in 10 studies
Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.
dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients were assessed for nausea and vomiting on their infusion day using the Multinational Association of Supportive Care in Cancer Antiemesis Tool (MAT) at arrival, pre-ASCT infusion, pre-ondansetron administration, prior to the first bag, and after each bag of stem cells." | 9.17 | Prevention of dimethylsulfoxide-related nausea and vomiting by prophylactic administration of ondansetron for patients receiving autologous cryopreserved peripheral blood stem cells. ( Eisenberg, S; Gooley, T; Holmberg, L; Linenberger, M; Wickline, M, 2013) |
| "Patients were assessed for nausea and vomiting on their infusion day using the Multinational Association of Supportive Care in Cancer Antiemesis Tool (MAT) at arrival, pre-ASCT infusion, pre-ondansetron administration, prior to the first bag, and after each bag of stem cells." | 5.17 | Prevention of dimethylsulfoxide-related nausea and vomiting by prophylactic administration of ondansetron for patients receiving autologous cryopreserved peripheral blood stem cells. ( Eisenberg, S; Gooley, T; Holmberg, L; Linenberger, M; Wickline, M, 2013) |
| " Patients were monitored for adverse events (AEs), coagulation markers, PLT responses, and hemostatic efficacy." | 2.87 | Safety and efficacy of cryopreserved platelets in bleeding patients with thrombocytopenia. ( Cancelas, JA; Dumont, LJ; Dunbar, NM; Gernsheimer, TB; Hmel, P; Housler, G; Jones, M; Kinne, B; Macdonald, VW; Medlin, S; Prakash, G; Ransom, JH; Rugg, N; Slichter, SJ; Szczepiorkowski, ZM; Valiyaveettil, M, 2018) |
| " A variety of adverse events (AEs) of varying severity have been noted during HPC infusions." | 1.40 | Infusion technique of hematopoietic progenitor cells and related adverse events (CME). ( Bryant, SC; Gastineau, DA; Greiner, CW; Hogan, WJ; Jacob, EK; Lingineni, RK; Mohr, A; Mulay, SB; Padley, D, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Slichter, SJ | 1 |
| Dumont, LJ | 1 |
| Cancelas, JA | 1 |
| Jones, M | 1 |
| Gernsheimer, TB | 1 |
| Szczepiorkowski, ZM | 1 |
| Dunbar, NM | 1 |
| Prakash, G | 1 |
| Medlin, S | 1 |
| Rugg, N | 1 |
| Kinne, B | 1 |
| Macdonald, VW | 1 |
| Housler, G | 1 |
| Valiyaveettil, M | 1 |
| Hmel, P | 1 |
| Ransom, JH | 1 |
| Eisenberg, S | 1 |
| Wickline, M | 1 |
| Linenberger, M | 1 |
| Gooley, T | 1 |
| Holmberg, L | 1 |
| Mulay, SB | 1 |
| Greiner, CW | 1 |
| Mohr, A | 1 |
| Bryant, SC | 1 |
| Lingineni, RK | 1 |
| Padley, D | 1 |
| Hogan, WJ | 1 |
| Gastineau, DA | 1 |
| Jacob, EK | 1 |
| Spoerl, S | 1 |
| Peter, R | 1 |
| Krackhardt, AM | 1 |
| Ozdemir, E | 1 |
| Akgedik, K | 1 |
| Akdogan, S | 1 |
| Kansu, E | 1 |
| Horacek, JM | 1 |
| Jebavy, L | 1 |
| Jakl, M | 1 |
| Zak, P | 1 |
| Mericka, P | 1 |
| Maly, J | 1 |
| Akkök, CA | 1 |
| Liseth, K | 1 |
| Melve, GK | 1 |
| Ersvaer, E | 1 |
| Hervig, T | 1 |
| Bruserud, Ø | 1 |
| Almici, C | 1 |
| Ferremi, P | 1 |
| Lanfranchi, A | 1 |
| Ferrari, E | 1 |
| Verardi, R | 1 |
| Marini, M | 1 |
| Rossi, G | 1 |
| Sputtek, A | 1 |
| Jetter, S | 1 |
| Hummel, K | 1 |
| Kühnl, P | 1 |
| Chun, EM | 1 |
| Park, YJ | 1 |
| Kang, HS | 1 |
| Cho, HM | 1 |
| Jun, DY | 1 |
| Kim, YH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Dose Escalation Study Evaluating the Safety of Dimethyl Sulfoxide Cryopreserved Platelets Compared With Liquid Stored Platelets in Patients With Uncontrolled Bleeding[NCT02078284] | Phase 1 | 28 participants (Actual) | Interventional | 2014-11-05 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Subjects with any signs or symptoms of thrombotic events. (NCT02078284)
Timeframe: 6 days after transfusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 With 0.5 Units of CPP | 0 |
| Cohort 2 With 1 Unit of CPP | 0 |
| Cohort 3 With 2 Units of CPP | 0 |
| Cohort 4 With 3 Units of CPP | 0 |
| 1 Unit of LSP | 0 |
Clinical laboratory [chemistry (serum creatinine, lactate dehydrogenase (LDH), and troponin, and hematology (hemoglobin and hematocrit)] parameters, physical examination findings, electrocardiogram (ECG)] and vital sign AEs summarized by severity. (NCT02078284)
Timeframe: day of thru 6 days after transfusion
| Intervention | adverse events (Number) | ||||
|---|---|---|---|---|---|
| Total number of AEs | Total mild AEs | Total moderate AEs | Total Severe AEs | Total Life-threatening or Fatal AEs | |
| 1 Unit of LSP | 5 | 5 | 0 | 0 | 0 |
| Cohort 1 With 0.5 Units of CPP | 8 | 6 | 1 | 0 | 1 |
| Cohort 2 With 1 Unit of CPP | 18 | 11 | 3 | 1 | 3 |
| Cohort 3 With 2 Units of CPP | 6 | 1 | 5 | 0 | 0 |
| Cohort 4 With 3 Units of CPP | 21 | 9 | 5 | 1 | 6 |
Corrected Count Increments Expressed in units of mm^2/(µL*10¹¹ platelets) (CCI) in the 6 hour period after the study platelet transfusion and on Day 2 (approximately 24 hours after the study platelet transfusion) (NCT02078284)
Timeframe: Day 1 up to 6 hrs after transfusion and Day 2 approx 24 hrs after transfusion
| Intervention | mm^2/(μL*1011 platelets) (Mean) | |
|---|---|---|
| CII: Day 1 up to 6 hrs after | CII: Day 2 | |
| 1 Unit of LSP | 14.8 | 4.13 |
| Cohort 1 With 0.5 Units of CPP | 2.40 | 5.19 |
| Cohort 2 With 1 Unit of CPP | 3.10 | -2.05 |
| Cohort 3 With 2 Units of CPP | 2.73 | 5.63 |
| Cohort 4 With 3 Units of CPP | 3.70 | 2.35 |
Count Increment expressed in units of platelets (x10^3 µL) (CI) (NCT02078284)
Timeframe: On Day 1 up to 6 hours after transfusion and on Day 2 approximately 24 hours after transfusion
| Intervention | platelets*10^3 µL (Mean) | |
|---|---|---|
| Day 1 Up to 6 Hours After | Day 2 | |
| 1 Unit of LSP | 30.5 | 8.75 |
| Cohort 1 With 0.5 Units of CPP | 1.20 | 2.80 |
| Cohort 2 With 1 Unit of CPP | 3.67 | -2.57 |
| Cohort 3 With 2 Units of CPP | 6.50 | 12.5 |
| Cohort 4 With 3 Units of CPP | 13.2 | 10.7 |
Number of subjects who experienced AEs at specific levels of severity. Clinical laboratory [chemistry (serum creatinine, lactate dehydrogenase (LDH), and troponin, and hematology (hemoglobin and hematocrit)] parameters, physical examination findings, electrocardiogram (ECG)] and vital signs were evaluated. (NCT02078284)
Timeframe: day of thru 6 days after transfusion
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Total Patients with Any AE | Total Patients with Mild AEs | Total Patients with Moderate AEs | Total Patients with Severe AEss | Total Patients with Life-threatening or Fatal AEs | Related to Investigational Product | ||
| 1 Unit of LSP | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Cohort 1 With 0.5 Units of CPP | 4 | 4 | 4 | 1 | 0 | 1 | 1 |
| Cohort 2 With 1 Unit of CPP | 6 | 6 | 4 | 1 | 1 | 1 | 2 |
| Cohort 3 With 2 Units of CPP | 3 | 3 | 1 | 3 | 0 | 2 | 2 |
| Cohort 4 With 3 Units of CPP | 5 | 5 | 5 | 1 | 1 | 2 | 2 |
2 reviews available for dimethyl sulfoxide and Hematologic Malignancies
| Article | Year |
|---|---|
Cryopreservation in Closed Bag Systems as an Alternative to Clean Rooms for Preparations of Peripheral Blood Stem Cells.
Topics: Cryopreservation; Cryoprotective Agents; Dimethyl Sulfoxide; Environment, Controlled; Glycerol; Hema | 2016 |
Is there a scientific basis for a recommended standardization of collection and cryopreservation of peripheral blood stem cell grafts?
Topics: Cryopreservation; Dimethyl Sulfoxide; Evidence-Based Medicine; Hematologic Neoplasms; Hematopoietic | 2011 |
2 trials available for dimethyl sulfoxide and Hematologic Malignancies
| Article | Year |
|---|---|
Safety and efficacy of cryopreserved platelets in bleeding patients with thrombocytopenia.
Topics: Adult; Aged; Blood Preservation; Cell-Derived Microparticles; Cryopreservation; Cryoprotective Agent | 2018 |
Prevention of dimethylsulfoxide-related nausea and vomiting by prophylactic administration of ondansetron for patients receiving autologous cryopreserved peripheral blood stem cells.
Topics: Antiemetics; Blood Transfusion, Autologous; Cohort Studies; Cryoprotective Agents; Dimethyl Sulfoxid | 2013 |
6 other studies available for dimethyl sulfoxide and Hematologic Malignancies
| Article | Year |
|---|---|
Infusion technique of hematopoietic progenitor cells and related adverse events (CME).
Topics: Acetaminophen; Adolescent; Adult; Aged; Blood Preservation; Child; Child, Preschool; Cryopreservatio | 2014 |
The lollipop with strawberry aroma may be promising in reduction of infusion-related nausea and vomiting during the infusion of cryopreserved peripheral blood stem cells.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Allergic Agents; Candy; Cryopreservation; Cryoprote | 2008 |
Cardiovascular changes associated with infusion of hematopoietic cell grafts in oncohematological patients -- impact of cryopreservation with dimethylsulfoxide.
Topics: Blood Pressure; Cardiovascular System; Cryopreservation; Cryoprotective Agents; Dimethyl Sulfoxide; | 2009 |
Uncontrolled-rate freezing of peripheral blood progenitor cells allows successful engraftment by sparing primitive and committed hematopoietic progenitors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Preservation; Cell Co | 2003 |
Cryopreservation of peripheral blood progenitor cells: characteristics of suitable techniques.
Topics: Blood Preservation; Cell Survival; Colony-Forming Units Assay; Cryopreservation; Cryoprotective Agen | 1997 |
Expression of the apolipoprotein C-II gene during myelomonocytic differentiation of human leukemic cells.
Topics: 3T3 Cells; Animals; Apolipoprotein C-II; Apolipoproteins C; Carcinoma; Cell Differentiation; Cyclin | 2001 |